Clinical trial
PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After…
NCT00088660 · Therion Biologics Corporation, Industry · Unknown status
Key facts
| NCT number | NCT00088660 |
|---|---|
| Title | PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen |
| Official title | A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy… |
| Lead sponsor | Therion Biologics Corporation, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological |
| Interventions | PANVAC™-VF |
| Enrollment | 250 |
| Start date | Jun 1, 2004 |
| First posted | Aug 2, 2004 |
| Last update posted | Feb 8, 2006 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: